Analyzing a Randomized Cancer Prevention Trial with a Missing Binary Outcome, an Auxiliary Variable, and All-or-None Compliance

By Baker, Stuart G. | Journal of the American Statistical Association, March 2000 | Go to article overview

Analyzing a Randomized Cancer Prevention Trial with a Missing Binary Outcome, an Auxiliary Variable, and All-or-None Compliance


Baker, Stuart G., Journal of the American Statistical Association


The Prostate Cancer Prevention Trial is a randomized chemoprevention trial designed to compare the effect of daily finasteride versus placebo on prostate cancer determined by biopsy. Investigators have scheduled a biopsy at the end of the trial in 7 years or following a positive prostate-specific antigen (PSA) on annual screening. The analysis will need to adjust for two likely complications. First, some subjects will not receive a biopsy, depending in part on whether or not they had a positive PSA. The indicator of positive PSA is called an auxiliary variable, which is a variable observed after randomization and prior to outcome. Second, starting soon after randomization, some subjects randomized to finasteride will stop taking their tablets, and some subjects randomized to placebo will obtain finasteride outside of the trial. This type of noncompliance is called all-or-none. To adjust for these complications, we formulate the appropriate likelihoods and obtain closed-form maximum likelihood estimates and va riances. Without these adjustments, estimates may be biased, two-sided type I errors above nominal levels, and coverage of confidence intervals below nominal levels.

KEY WORDS: Finasteride; Nonignorable missing data; Prostate Cancer Prevention Trial; Randomized trials.

1. INTRODUCTION

The Prostate Cancer Prevention Trial (PCPT) is a chemoprevention trial in which 18,000 men age 55 and older were randomized to either daily finasteride or placebo tablets for 7 years. The primary goal is to determine whether subjects assigned to finasteride have a different prevalence of prostate cancer determined by biopsy than subjects randomized to placebo. (For more details of the study design, see Feigl et al. 1994.) The trial, which involves 222 sites in the United States, opened in 1993, and recruitment was completed in 1996. Researchers from the Southwest Oncology Group are coordinating the study, which also involves researchers from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. The study is funded by the National Cancer Institute. Merck and Co., Inc. is providing both the finasteride and the placebo at no charge.

Because the outcome of the study is prostate cancer determined by biopsy, investigators scheduled all subjects to receive a biopsy at the end of the trial. To increase support for the trial among urologists, investigators also scheduled an annual screening test for prostate-specific antigen (PSA) with a biopsy for those testing positive. The investigators defined a positive PSA in the placebo group as a PSA level above 4.0 ng/mL. Because finasteride lowers PSA levels, the investigators defined a positive PSA in the finasteride group as a PSA above a specific level such that the same percentage is positive as in the placebo group. We say that PSA is an auxiliary variable, because it is observed after randomization and prior to endpoint.

Feigl et al. (1994) anticipated that 23% of the 18,000 subjects will not receive a biopsy due to loss to follow-up or refusal. One analytic challenge is to adjust for missing outcome data when biopsy depends on the auxiliary variable.

In Sections 2, 3, and 4 I discuss missing-data adjustments under an intent-to-treat (ITT) analysis. In Section 2 I discuss model B, a basic adjustment in which biopsy depends only on assigned treatment. In Section 3 I present model A, an adjustment using the auxiliary variable, and in Section 4 I generalize model A to model AM, which allows a missing auxiliary variable.

Feigl et al. (1994) also anticipated that 5% of subjects in the placebo arm will receive finasteride outside the trial and that 14% of subjects in the finasteride arm will not take their tablets. (Investigators are monitoring finasteride use via serum dihydrotestosterone levels). A second analytic challenge is to adjust for this all-or-none compliance (ANC) by extending the models of Angrist, Imbens, and Rubin (1996), Baker (1998a, 1998b), Baker and Lindeman (1994), Frangakis and Rubin (1998), and Sheiner and Rubin (1995).

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Analyzing a Randomized Cancer Prevention Trial with a Missing Binary Outcome, an Auxiliary Variable, and All-or-None Compliance
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.